跳至主要内容
临床试验/JPRN-UMIN000001853
JPRN-UMIN000001853已完成2 期

Preventive effect of shakuyaku-kanzo-to on neurotoxicity of FOLFOX plus bevacizumab for patients with metastatic colorectal cancer: a prospective phase II study - Preventive effect of shakuyaku-kanzo-to on neurotoxicity of FOLFOX plus bevacizumab

niversity of Toyama0 个研究点目标入组 40 人开始时间: 2009年4月6日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Active other malignancies 2. Brain metastasis 3. Massive pleural effusion or ascites 4. History of severe drug hypersensitivity 5. Uncontrollable hepertension 6. Severe complications(ileus, interstitial pneumonitis, pulmonary fibrosis, uncontrollable diabetes mellitus, heart failure) 7. History of thromboembolitic disease 8. Bleeding diathesis 9. Active peptic ulcer 10. Active infectious disease 11. Uncontrollable watery diarrhea 12. Peripheral neuropathy 13. Aldosteronism 14. Myopathy 15. Surgical procedure within 4 weeks before registration 16. Psychosis 17. Pregnant or lactating woman 18. Not appropriate for the study at the physician's assessmnt

研究者

发起方
niversity of Toyama

相似试验